SJShengjie Jin

Shengjie Jin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shengjie Jin has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Dousheng Bai

    Department of Hepatobiliary Surgery, Northern Jiangsu People’s Hospital Affiliated to Yangzhou University, Yangzhou, China

    4 shared publications
  • Jun Cao

    Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University. No. 98 West Nantong Road, Yangzhou, Jiangsu, 225009, P.R. China; General Surgery Institute of Northern Jiangsu People's Hospital, Yangzhou, China

    3 shared publications
  • Bing-Bing Su

    Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital Affliated to Yangzhou University, Yangzhou City, Jiangsu Province, China

    2 shared publications
  • Chi Zhang

    Department of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University, Yangzhou, China

    2 shared publications
  • Guo-Qing Jiang

    Department of General Surgery, Northern Jiangsu People’s Hospital, Yangzhou, China

    2 shared publications
  • Jiahao Zhang

    Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University. No. 98 West Nantong Road, Yangzhou, Jiangsu, 225009, P.R. China

    2 shared publications

Latest Publications

  • Open Access

    CircSPECC1 attenuates sensitivity to PD-1 blockade through impaired antigen presentation in hepatocellular carcinoma

    by Rui Peng, Jiahao Zhang, Chi Zhang, Bingbing Su, Songsong Fan, Yongzhi Chen, Qian Wang, Guoqing Jiang, Li Ding, Xin Jin, et al.

  • Open Access

    Degradation of PARP1 by MARCHF3 in tumor cells triggers cCAS-STING activation in dendritic cells to regulate antitumor immunity in hepatocellular carcinoma

    by Jun Cao, Bingbing Su, Chi Zhang, Rui Peng, Daoyuan Tu, Qiangwei Deng, Guoqing Jiang, Shengjie Jin, Qian Wang, Dou-Sheng Bai

    Background: Resistance to immune checkpoint inhibitors (ICIs) significantly limits the efficacy of immunotherapy in patients with hepatocellular carcinoma (HCC). However, the mechanisms underlying immunotherapy resistance remain poorly understood. Our aim was to clarify the role of membrane-associated ring-CH-type finger 3 (MARCHF3) in HCC within the framework of anti-programmed cell death protein-1 (PD-1) therapy. Methods: MARCHF3 was identified in the transcriptomic profiles of HCC tumors exhibiting different responses to ICIs. In humans, the correlation between MARCHF3 expression and the tumor microenvironment (TME) was assessed via multiplex immunohistochemistry. In addition, MARCHF3 expression in tumor cells and immune cell infiltration were assessed by flow cytometry. Results: MARCHF3 was significantly upregulated in tumors from patients who responded to ICIs. Increased MARCHF3 expression in HCC cells promoted dendritic cell (DC) maturation and stimulated CD8+ T-cell activation, thereby augmenting tumor control. Mechanistically, we identified MARCHF3 as a pivotal regulator of the DNA damage response. It directly interacted with Poly(ADP-Ribose) Polymerase 1 (PARP1) via K48-linked ubiquitination, leading to PARP1 degradation. This process promoted the release of double-strand DNA and activated cCAS-STING in DCs, thereby initiating DC-mediated antigen cross-presentation and CD8+ T-cell activation. Additionally, ATF4 transcriptionally regulated MARCHF3 expression. Notably, the PARP1 inhibitor olaparib augmented the efficacy of anti-PD-1 immunotherapy in both subcutaneous and orthotopic HCC mouse models. Conclusions: MARCHF3 has emerged as a pivotal regulator of the immune landscape in the HCC TME and is a potent predictive biomarker for HCC. Combining interventions targeting the DNA damage response with ICIs is a promising treatment strategy for HCC.


  • Strategic advancement of E3 ubiquitin ligase in the management of hepatocellular carcinoma

    by Yangyang Miao, Shunyi Wang, Jiahao Zhang, Huanxiang Liu, Chi Zhang, Shengjie Jin, Dousheng Bai

    Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its high incidence, poor prognosis, and limited treatment options. As a pivotal regulator of protein stability, E3 ubiquitin ligase plays a crucial role in tumorigenesis and development. This review provides an overview of the latest research on the involvement of E3 ubiquitin ligase in hepatocellular carcinoma and elucidates its significance in hepatocellular carcinoma cell proliferation, invasion, and evasion from immune surveillance. Special attention is given to the functions of RING, HECT, and RBR E3 ubiquitin ligases and their association with hepatocellular carcinoma progression. By dissecting the molecular mechanisms and regulatory networks governed by E3 ubiquitin ligase, several potential therapeutic strategies are proposed: including the development of specific inhibitors targeting E3 ligases; augmentation of their tumor suppressor activity through drug or gene therapy; utilization of E3 ubiquitin ligase to modulate immune checkpoint proteins for improved efficacy of immunotherapy; combination strategies integrating traditional therapies with E3 ubiquitin ligase inhibitors; as well as biomarker development based on E3 ubiquitin ligase activity. Furthermore, this review discusses the prospect of overcoming drug resistance in hepatocellular carcinoma treatment through these novel approaches. Overall, this review establishes a theoretical foundation and offers fresh insights into harnessing the potential of E3 ubiquitin ligase for treating hepatocellular carcinoma while highlighting future research directions that pave the way for clinical translation studies and new drug discoveries.


  • Open Access

    In vivo CRISPR screen identifies LTN1 as a novel tumor suppressor ubiquitinating insulin–like growth factor 2 mRNA–binding protein 1 in hepatocellular carcinoma

    by Rui Peng, Jun Cao, Chi Zhang, Jie Zhou, Bing-Bing Su, Dao-Yuan Tu, Guo-Qing Jiang, Sheng-Jie Jin, Ya-Ping Xu, Dou-Sheng Bai

    Background and Aims: Hepatocellular carcinoma (HCC) is a frequent and aggressive kind of cancer. Although E3 ligases play important roles in HCC development, several E3 ligases remain unknown. Approach and Results: Through in vivo CRISPR knockout (KO) screens targeting related E3 ligase genes in HCC nude mice models, we discovered LTN1 as a novel tumor suppressor in HCC. Co-IP paired with 2D-LC-MS/MS and subsequent western blotting in HCC cells were used to identify the interactome of LTN1. Compared to matched normal tissues, the expression of LTN1 was decreased in human HCC tissues (ANT) (157/209). Clinically, patients with HCC who expressed low levels of LTN1 had a poor prognosis. Forced expression of LTN1 decreased cell growth in vitro and in vivo, whereas knockdown of LTN1 increased cell growth. Mechanistically, elevated LTN1 expression inhibited HCC cell growth by ubiquitinating and destabilizing the IGF2BP1 protein, which inhibited the c-Myc and IGF-1R signaling pathways. There was a negative correlation between the LTN1 protein expression and the IGF2BP1 protein expression in HCC tissues (R2=0.2799, P=0.0165). Conclusions: LTN1 may be a crucial tumor suppressor for determining the prognosis and a possible therapeutic target since it inhibits the proliferation of HCC cells by ubiquitinating IGF2BP1.